The UK and US have announced a landmark trade agreement that will keep zero duties on UK drug exports going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost spending on medicines through the NHS. This pledge secures that duties on these vital products will stay at zero for a duration of the next three years.
This agreement is in response to previous threats to hike import taxes on branded drug products, with figures floated reaching one hundred percent.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and brings long-overdue balance to American-British drug exports," a statement declared.
Economic Impact
Drugs are one of the the United Kingdom's biggest export categories to the America, which is easily the largest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to September, the UK shipped medicines totaling £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards employment, stimulates funding and facilitates the UK to become a worldwide center for medical research," a government official commented.
Specific British Pledges
The pact includes several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to double total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be limited at fifteen percent. Previously, rebates topped 20%.
Broader Context
The deal comes amid a protracted tension between the sector and the ministers over spending levels and approval rates.
The disagreement were exacerbated by claims that American patients were charged several times more for the same drugs than people in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the previous ten-year period.
